Tag: SPM

Health Care

DKSH Supports Growth for Vitabiotics in Hong Kong and Malaysia

admin

DKSH, the leading Market Expansion Services provider with a focus on Asia, and Vitabiotics, Britain’s largest and fastest growing major vitamin supplement company, has signed an agreement to expand the firm’s product range into Hong Kong and Malaysia.

BANGKOK, April 8, 2015 /PRNewswire/ — DKSH Business Unit Healthcare, a leading partner for healthcare companies seeking to grow their business in Asia, will provide marketing, sales, distribution, logistics and regulatory services for Vitabiotics in Hong Kong and Malaysia. The agreement is an extension of a collaboration that started in Taiwan in 2011.

DKSH will broaden Vitabiotics’ already established market position and product range in Hong Kong on offer by leveraging its reach and deepening distribution to more pharmacy outlets. The Vitabiotics range is also undergoing approval by authorities in Malaysia.

According to a recent study by Roland Berger Strategy Consultants, the Market Expansion Services market for over-the-counter healthcare products in Hong Kong is expected to grow by 5-6% annually between 2014 and 2019. Malaysia is expected to see a slightly higher growth rate of 6-7% growth per year over the same period.

“The diverse Asian market shows excellent long term growth potential for Vitabiotics’ products. Working with our regional partner DKSH allows us to accelerate our growth and enter new strategic markets at the same time. While we can focus on our core strengths, DKSH’s strong commitment to compliance and governance gives us the security that the expansion of our business is in safe hands,” said Robert Taylor, Vice President, Vitabiotics.

“Our regional reach and integrated services give Vitabiotics the convenience of working with one strategic partner across multiple markets. With the insights and commercial capabilities of our local experts and our broad capillary distribution, we are confident to spur further growth for Vitabiotics in Asia,” said Andrew Frye, Head of Business Healthcare, DKSH.

The agreement will strengthen DKSH’s market position in Asia over time.

About Vitabiotics

Vitabiotics has pioneered advances in nutritional healthcare for 45 years, a British company committed to human health and research. As the UK’s No.1 vitamin company, Vitabiotics has created a unique portfolio of products at the forefront of scientific developments in key sectors, with no fewer than 8 brands in the top 18 VMS brands in the UK, including Pregnacare, Osteocare, Wellman and Wellwoman. Vitabiotics is widely acknowledged as leaders in innovation and in 2013 became the first vitamin company to receive the Queen’s Award for Innovation, awarded for its ground breaking clinical research.

As the fastest growing major vitamin company in the UK, Vitabiotics exports to over 100 countries, and has twice received the Queen’s Awards for International Trade. Designed to provide maximum efficacy by supporting the human body in its own natural processes, each product is developed using the latest research available and is produced to the highest pharmaceutical standards.

About DKSH

DKSH is the leading Market Expansion Services provider with a focus on Asia. As the term “Market Expansion Services” suggests, DKSH helps other companies and brands to grow their business in new or existing markets.

Publicly listed on the SIX Swiss Exchange since March 2012, DKSH is a global company headquartered in Zurich. With 750 business locations in 35 countries — 720 of them in Asia — and 27,600 specialized staff, DKSH generated net sales of CHF 9.8 billion in 2014.

In 2015, DKSH celebrates its 150th anniversary. With strong Swiss heritage, the company has a long tradition of doing business in and with Asia, and is deeply rooted in communities and businesses across Asia Pacific.

DKSH Business Unit Healthcare is the leading Market Expansion Services provider for healthcare companies seeking to grow their business in Asia. Custom-made offerings comprise registration, regulatory services, market entry studies, importation, customs clearance, marketing and sales, physical distribution, invoicing and cash collection. Products available through DKSH Healthcare include pharmaceuticals, consumer health and over-the-counter (OTC) products, as well as medical devices. With 150 business locations in 14 countries and around 9,200 specialized staff, Business Unit Healthcare serves over 150,000 customers and generated net sales of around CHF 4.5 billion in 2014.

Health Care

Fi Asia-China, Hi & Ni to Open at SNIEC, Shanghai, 24-26 June 2015

admin

Where food, pharma & nutraceuticals meet

SHANGHAI, March 25, 2015 /PRNewswire/ — China’s leading food and nutritional ingredient show returns to Shanghai this June with more exhibitors, features, visitors, ingredients and opportunities. More than 3,500 exhibitors and over 64,000 other industry professionals will come together to focus on sourcing the latest Chinese and Pan-Asian product innovations, market trends and the latest technologies at this key industry event. Taking place from 24-26 June 2015, Fi Asia-China will be co-located with 6 other events including Healthplex and Nutraceutical China (HNC) and CPhI China, which visitors can access for free.

HNC conference

HNC conference

 

Match Making

Match Making

 

Onsite Visitors

Onsite Visitors

 

 

 

Top exhibitors that will be ready to do business and showcase their latest products and innovations include leading companies ConTek, DuPont, Gelita, Mintel, Naturex, Neptune Technologies, Plant Lipids, POM Wonderful, The Rimfrost Group, Rousselot and many more!

Features and highlights:

Health ingredients

A key and unique area of the show is Health ingredients Asia–China, where over 90 Chinese exhibitors will be present. This area will feature key exhibitors specialising in health and nutraceutical ingredients. China is the biggest nutraceutical ingredient exporter in the world and as of January 2014, the exports were valued at more than USD 24 million with a rise of 26% against 2013. The United States, Japan and Chile are the top three export markets for China’s health ingredients and the most popular products include fish oil, beeswax, lecithin and pollen, and are currently being exported to 98 countries.

Natural ingredients

Natural ingredients Asia–China is the largest gathering of leading suppliers specialising in natural and functional food and beverage ingredients. Here, visitors can source the latest technologies and trends, staying ahead of the competition.

Conferences

The two-day conference programme organised by the China Chamber of Commerce for Import & Export of Medicines & Health Products, will offer expert insight in topics such as functional beverages, nutrition and health food analysis, Chinese food safety standards, import and export regulations and developments, processes for international dietary supplements and more!

Global Buyer’s Sourcing Meeting

This feature has established thousands of successful face-to-face meetings for international buyers from over 100 countries, helping them build business relationships with Chinese suppliers. You can pre-arrange one-to-one meetings with the right suppliers you need through this feature and maximise your time at the show. Held annually since 2009, the Global Buyers Sourcing Meeting is an onsite service provided at Fi Asia-China by our partner 21Food.

Mobile App

The Fi Asia-China mobile app is free to download and allows visitors to easily organise and customise their day, with all the key information available at their fingertips. Connect with exhibitors, access all on-site features, easily navigate through the 17 halls, arrange your on-site agenda, expand your professional network and engage with the 64,000+ on-site attendees to the show. The app is available from April onwards.

Co-located events

Fi Asia-China is co-located with a powerhouse of 6 other events, making it the most cost-effective one-stop shop for food ingredients industry professionals. Visit Health ingredients and Natural ingredients Asia–China, Healthplex and Nutraceuticals China, Expo Food Tec, Starch Expo and CPhI and P-MEC China and source the latest ingredients and innovations across the entire value chain over the 3 show days.

Registration is free and can be done at www.fi-asia-china.com.

Photo – http://photos.prnasia.com/prnh/20150325/8521501831
Photo – http://photos.prnasia.com/prnh/20150325/8521501831b
Photo – http://photos.prnasia.com/prnh/20150325/8521501831c
Logo – http://photos.prnasia.com/prnh/20150325/8521501831logo
Logo – http://www.prnasia.com/sa/2010/04/19/20100419602891.jpg  

Fashion HOU

Frost & Sullivan Honours Mibelle Biochemistry for its Discovery of Snow Algae Powder, an Active Ingredient for Anti-Ageing Skin Care Products

admin

– Mibelle Biochemistry has perfectly combined natural resources and biotechnology to produce the peerless Snow Algae Powder

LONDON, March 12, 2015 /PRNewswire/ — Based on its recent analysis of the anti-ageing skin care market, Frost & Sullivan recognizes Mibelle Biochemistry with the 2014 European Award for New Product Innovation Leadership.

Click here for the full multimedia experience of this release – http://bit.ly/1zRh8X9

Mibelle Biochemistry has been highly successful in leveraging its technological expertise to produce Snow Algae Powder, an active ingredient for anti-ageing skincare products. By combining sustainable technology with effective production methods, Mibelle Biochemistry has designed the most productive active agent for the cosmetic industry.

The production process of the active ingredient involves initial isolation of the algae, followed by enhanced cultivation in bio-reactors.  Optimal cultivation of the Snow Algae Powder in the bio-reactor enhances the production of stress response molecules, eg. carotenoids which are very valuable for the skin. Further, the snow algae are harvested for purification, the cell walls of the algae are disrupted and the cell fragments are encapsulated into liposomes. Finally, the algae are spray-dried on a maltodextrin-based powder.

Mibelle Biochemistry’s advanced encapsulation technology enables optimum bioavailability of the extract. Its best practices also guarantee that the ingredient is uncontaminated by pollutants or pesticides.

The Snow Algae Powder stimulates Klothogene, a highly efficient anti-ageing stimulant, by as much as 47 percent. The resulting boost in the activated protein kinase α (AMPK) creates a protective cover against excess calories and prevents the reduction of AMPK over age.

“Snow algae are the only algae that increase the amount of Klothogene in the skin. It helps in DNA repair and detoxification of skin cells, and stimulates calorie restriction mimetics,” said Frost & Sullivan Vice President Shomik Majumdar. “Furthermore, with this ingredient, Mibelle Biochemistry pioneered the improvement of the papillary structure at the dermal-epidermal junction for skin rejuvenation.”

Additionally, Snow Algae Powder can neutralize collagen degradation by stimulating its production and forming a barrier against the enzymes that destroy collagen. It also reduces water loss of the skin through the epidermis, thereby reducing dryness and skin ageing.

Mibelle Biochemistry has not only focused on producing superior products but has also educated its customers and end users on the benefits of snow algae and their cultivation. It allows its customers to use the logo of Snow Algae Powder, free of cost, on the label of the final product.

Mibelle Biochemistry has patented use of snow algae extract in cosmetics, giving it a first-mover advantage. Frost & Sullivan expects its unique strategy in marketing the product as a whole package to drive its rapid adoption.

“Mibelle Biochemistry uses zero preservatives and consistent concentration of metabolites,” noted Industry Analyst Nandhini Rajagopal. “This strict procedure and its customized bio-reactors ensure that the Snow Algae Powder offers superior quality and unmatched value to customers.”

Each year, Frost & Sullivan presents this award to the company that has developed an innovative element in a product by leveraging leading-edge technologies. The award recognizes the value added features/benefits of the product and the increased ROI it offers customers, which in turn increases customer acquisition and overall market penetration potential.

Frost & Sullivan Best Practices awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis and extensive secondary research to identify best practices in the industry.

About Mibelle Biochemistry

Inspired by nature – Realized by science

Mibelle Biochemistry, a Swiss company, is specialized in the research and development of innovative, high-quality actives for the cosmetic industry. Inspired by nature Mibelle Biochemistry transforms naturally derived compounds into truly functional cosmetic ingredients. Furthermore Mibelle Biochemistry possesses powerful encapsulation technologies that guarantee optimum bioavailability. All products are accompanied by comprehensive technical support and marketing-oriented documentation.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants.

Our “Growth Partnership” supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

  • The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
  • The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact Us: Start the discussion
Join Us: Join our community
Subscribe: Newsletter on “the next big thing”
Register: Gain access to visionary innovation

Contact:

Beata Hurst
Head of  Marketing
Mibelle Biochemistry
beata.hurst@mibellegroup.com
Phone: +41-62-836-17-46

Kristina Menzefricke
Best Practices
Frost & Sullivan
kristina.menzefricke@frost.com
P: +44-(0)20-7915-7869

Health Care

Frost & Sullivan Applauds Neopeutics’ Commitment to Accelerating the Delivery of New Nature-Based Pharmaceuticals and Therapeutics

admin

Neopeutics has shown integrity in partnering with its customers at every stage of the drug discovery process

MOUNTAIN VIEW, Calif., March 3, 2015 /PRNewswire/ — Based on its recent analysis of the enhanced drug discovery market, Frost & Sullivan recognizes Neopeutics, Inc. with the 2015 North America Frost & Sullivan Award for Technology Leadership. Neopeutics has demonstrated a remarkable ability to innovate by offering clients a robust, cost-effective, and easily adaptable set of drug discovery instruments. It uniquely focuses on agents that are catalogued as failing compounds in the early stages of the drug discovery process, enabling customers to lower attrition rates and save drug development costs.

Neopeutics recognized with the 2015 North American Enhanced Drug Discovery Technology Leadership Award

Neopeutics recognized with the 2015 North American Enhanced Drug Discovery Technology Leadership Award

Photo – http://photos.prnasia.com/prnh/20150303/8521501311
Photo – http://photos.prnewswire.com/prnh/20150302/178914

Neopeutics’ contract research activities for regulatory agencies and industry players mainly comprise drug-discovery assistance, data analysis and interpretation, advisory and value-add services, and quality assurance (QA). Therefore, its main products are bioinformatics software, drug screening technology packages, and therapeutic compounds derived from natural resources.

One of the main distinguishing factors of Neopeutics is its dedication to introducing natural herbal products, pharmaceuticals, and therapeutics in the global biopharmaceutical market. It is achieving this through a multi-service drug discovery hub for nature-based therapeutics, which offers a distinct, affordable, high-standard QA/quality control (QC) service. Its end-to-end set of bioinformatics tools and expertise greatly assists the development of flexible, customized software tools such as genomics and proteomics platforms for drug screening and discovery.

Neopeutics’ technology platform has been commercialized not only among large pharmaceutical companies, but also small and medium enterprises, aiding the analysis of nature-based herbal products and nutraceuticals. During the screening phase, bioactive ingredients are extracted, separated, analyzed, and then profiled according to their potential therapeutic action.

“Neopeutics’ technology platform speeds up the identification of new therapeutic candidates by elucidating the mechanisms of action and signaling pathways, followed by the chemical agents in several in silico models,” said Frost & Sullivan Industry Analyst Cecilia Van Cauwenberghe. “Such early screening of compounds helps to guarantee a good safety profile for the agents under study.”

The company’s highly efficient and accurate technology helps determine the behavior of a wide range of compounds with their targets and allows the provision of QA services as a natural extension of its services. Since smaller manufacturers do not possess the facilities, financial resources, or expertise to perform QA, they will benefit greatly from Neopeutics’ techno-marketing. Similarly, it aids government regulatory agencies in establishing the mode of action and safety profiles of herbal medication, which is an important step in the regulatory and approval processes.

“Neopeutics is currently using a first-generation version of its proprietary software package of bioinformatics software tools for the drug screening market, while simultaneously working on launching its second-generation package,” noted Van Cauwenberghe. “It also leverages its bioinformatics capabilities to add value to other in-house, tailor-made solutions and enrich key components. Most of these services are coupled with assessment programs, as well as data analysis and interpretation services.”

Furthermore, the company has strategic advantages in terms of both geography and business development. Its two main locations in the United States and Malaysia are ideal to help it enhance business development activities with the major regional players.

Overall, for its strong integrative strategy and dedication to delivering novel nature-based pharmaceuticals, Neopeutics has been presented with the 2015 Frost & Sullivan Technology Leadership Award.

Each year, Frost & Sullivan presents this award to the company that has demonstrated uniqueness in developing and leveraging new technologies, which significantly impacts both the functionality and the customer value of the new products and applications. The award lauds the high R&D spend toward innovation, its relevance to the industry and the positive impact on brand perception.

Frost & Sullivan Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis and extensive secondary research to identify best practices in the industry.

About Neopeutics, Inc.

Neopeutics is an early stage drug discovery contract research partner that offers our partners and clients a robust and cost effective set of pre-clinical drug discovery tools. Our proprietary ChemoMAP® technology package is perfectly suited for “failing” compounds in the early stages of drug discovery, thereby helping to achieve notable savings in drug development costs. In addition, our discovery platform can also help our clients enhance the accuracy and speed of their “hit” identification process as well as elucidate the mode of action and confirm the efficacy and safety of their in-development and on-the-market products, thereby helping to improve drug safety and build consumer confidence.

As systems biology opens up limitless possibilities in drug discovery, we invite you to explore the horizon of drug discovery with us.

For more information, please visit www.neopeutics.com, or contact us at info@neopeutics.com.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants.

Our “Growth Partnership” supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

  • The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
  • The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact Us: Start the discussion
Join Us: Join our community
Subscribe: Newsletter on “the next big thing”
Register: Gain access to visionary innovation

Contact:
Mireya Espinoza
P: +1.210. 247.3870
F: +1.210.348.1003
E: mireya.espinoza@frost.com

Health Care

LKK Health Products Group Promotes Industrial Ecosystem

admin

GUANGZHOU, China, Dec. 12, 2014 /PRNewswire/ — LKK Health Products Group (LKKHPG) held its 7th Infinitus Supplier Conference themed “Cooperation Creates Value, Development Beholds Future” in Guangzhou on 28 November. Over 400 supplier representatives, employees and industrial experts attended the event.

Mr. Tim Chun, Senior Vice President of LKKHPG, delivered a keynote speech. He noted that it has become an important trend to establish industrial chains in a time of synergy and coexistence. Enterprises must push and strengthen cooperation with upstream and downstream partners within their industrial chains. Besides, they should insist on developing and creating value so as to win respect, revenues and a promising future.

“Infinitus” is the core brand of LKKHPG, whose members include Infinitus (China), Infinitus (Hong Kong), Infinitus (Taiwan) and Infinitus (Malaysia). Since its establishment in 1992, LKKHPG has adhered to its mission of “advocating the premium Chinese health regimen and nurturing healthier lives with balance, affluence, and harmony”. With product safety as the top priority, it is dedicated to providing high-quality TCM health products and services.

The Infinitus Supplier Conference has been organized annually for seven times in a row since 2008. It is intended to establish a communicative platform for both LKKHPG and its suppliers to share the latest trend and information of the industry and experience on corporate management and development. Meanwhile, based on its evaluation mechanism, LKKHPG evaluates its suppliers’ performances in a multi-dimensional way every year, and confers awards on those with outstanding performances at the conference.

In terms of quality management, LKKHPG holds on to its quality philosophy of “100-1=0” with an emphasis on comprehensive control over product quality. Furthermore, it applies its “Outstanding Supply Chain Management Model” to the five aspects of its whole supply chain, including R&D, raw material procurement, manufacturing and processing, logistics and market services. For internal management, it promotes its quality culture among all employees and applies quality management to every link of corporate management, while for external management, it closely cooperates with partners to forge the “community of interest” and the “community of responsibility”, in order to advance mutual development and sharing of responsibility. All these measures are taken to guarantee the comprehensive control over product quality.

Meanwhile, it actively carries out cooperation with authoritative universities and scientific institutions, such as the Hong Kong University of Science and Technology and the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, and has set up advisory boards to acquire professional advices from experts for further development of quality management. Besides, it regularly participates in seminars organized by governments and industrial associations around the globe to keep track of the latest advancements concerning product safety and ensure that its quality management aligns with the latest scientific and industrial developments and caters to consumers’ changing needs.

Mr. Harry Yeung, Senior Vice President of LKKHPG and Spokesperson of Infinitus, said, “LKKHPG aims to form an industrial ecosystem with a same goal and the same standards and to constantly enhance the capacity of the whole industrial chain. For years, we insist on establishing effective platforms and scientific mechanisms to encourage higher-standard synergy and development with the upstream and downstream partners and to drive the strategic compatibility between the suppliers and us, in order to provide consumers with safe, trustworthy and high-quality products and services.”

Photo – http://www.infinitus-int.com/news-detaile-141828764925270.html?l=en

Media Contact:
Samson Su
Tel: +86-20-3816-8859
Email: samson.su@infinitus-int.com

Fashion HOU

RevivSerums Launches Another Cosmetic Breakthrough: RevivLash with Redensyl

admin

SAN FRANCISCO, Nov. 21, 2014 /PRNewswire/ — Today RevivSerums introduces RevivLash, a revolutionary lash and brow restoration formula designed to give users thick, lush eyelashes and eyebrows. RevivLash is the first product of its kind to include award-winning Redensyl from Switzerland-based Induchem.

Logo – http://photos.prnewswire.com/prnh/20140730/132046

Redensyl won In-Cosmetics 2014 Silver Award for Best Personal Care Ingredient this spring.

The product combines two patented Induchem molecules – DHQG and EGCG2. These target hair follicle stems cells, reactivating the proliferation of stem cells.

“We’re delighted to add this new formula to our repertoire, and expect our customers will be delighted with the results: lush, thicker lashes & brows without breaking the bank,” said Jeff Havard, Director of Operations for RevivSerums.com.

Designed for both women and men, this next-generation leave-in serum can significantly help boost lash and brow length, thickness, strength and overall health.

Tester Christen Smith of Orange County CA noted, “I couldn’t be more impressed with this product. I saw new eyelashes begin to bud after just a few applications. I love the price point too, especially in comparison to Latisse.”

In addition to the incorporation of Redensyl, RevivLash contains several other remarkably effective actives: Keratinocyte Growth Factor (rh-Polypeptide-3), Myristoyl Pentapeptide-17 and Octapeptide-3.

In a 60-day, 28-person consumer study of RevivSerums’ new formula, 97% of testers said their eyelashes appeared longer or fuller, and 88% of respondents who applied the product to their brows said their eyebrows appeared thicker or fuller.

“RevivSerums.com is a great example of a company with an enthusiastic, creative culture and strong team delivering unique, on-trend products with compelling value. We are pleased to contribute to their further success and insatiable innovations with our cutting edge ingredients,” said Parand Salmassinia, General Manager of Induchem’s U.S.A. division.

RevivLash is specifically formulated to reduce potential for the irritation that occurs with other eyelash restoration products. Unlike Latisse(R) and LiLash(R), it contains no prostaglandin analogues, and is a cosmetic that can be purchased by consumers without having to obtain a prescription.

The new serum, a $100 value, debuts today for only $49 for a limited time. Its release coincides with Cosmetica Berlin, the definitive autumn beauty trade event in Europe. RevivLash is available immediately here at RevivSerums.com, which ships to most countries worldwide, and at select retailers, salons, medspas and physician’s offices.

Contact:
Bill Henderson
pressrelations@revivserums.com
+1-415-763-7248 x705

ERN Health Care

RM Group Announces FY2014-2015 Interim Results Profit Attributable to Owners of the Company Surges 111%

admin

HONG KONG, Nov. 12, 2014 /PRNewswire/ —

Financial Highlights

6 months ended 30 September

HK$’000

2014

2013

Change

Turnover

99,513

74,177

+34.2%

Gross profit

77,856

56,596

+37.6%

Gross profit margin

79.7%

78.4%

+1.3 ppt

Profit before taxation

11,024

5,954

+85.2%

Profit for the period attributable to owners of the Company

8,855

4,204

+110.6%

Earnings per share (basic) (HK cents)

1.72

1.09

+57.8%

RM Group Holdings Limited (“RM Group” or the “Company”, HKEx stock code: 8185) and its subsidiaries (the “Group”) announced its results for the six months ended 30 September 2014. During the reporting period, the Group recorded a turnover of approximately HK$99.5 million, representing an increase of approximately 34.2% as compared with the same period last year (2013: approximately HK$74.2 million). The profit for the period attributable to owners of the Company surges approximately 111% to approximately HK$8.9 million (2013: approximately HK$4.2 million).

Gross profit margin in the reporting period has increased 1.3 percentage point to 79.7% (2013: 78.4%).

Business Review

The Group is principally engaged in the business of formulation, marketing, sales and distribution of (i) health supplements and (ii) beauty supplements and products mainly in Hong Kong and Taiwan. The Group’s products are sold under its proprietary brands (including “Royal Medic”) and  private label brands specifically developed for and owned by a renowned retail chain of health and beauty products in Hong Kong and Macau (the “Distribution Facilitator”).

During the reporting period, health supplements remain the major source of income of the Group and have recorded continuous growth in turnover. For the six months ended 30 September 2014, the Group’s revenue attributable to health supplements increased approximately 56.5% to approximately HK$80.9 million (2013: approximately HK$51.7 million); while the revenue attributable to beauty supplements and products decreased approximately 17.6% to approximately HK$18.2 million (2013: approximately HK$22.1 million).

During the reporting period, the Group’s revenue attributable to proprietary brands health supplements increased 48.2% to approximately HK$60.6 million (2013: approximately HK$40.9 million), this is mainly due to the increase in sales of Royal Medic brand products. The revenue attributable to proprietary brands beauty supplements and products increased 1.9% to approximately HK$16.2 million (2013: approximately HK$15.9 million).

Due to the expansion of the Group’s product range and several existing popular private label brands products, which previously were only sold at special designated counters, were introduced to be sold on shelves as well in the stores of the Distribution Facilitator, the revenue attributable to private label brands health supplements increased significantly in the reporting period. It has surged approximately 82.4% to approximately HK$19.7 million (2013: approximately HK$10.8 million). Revenue attributable to private label brands beauty supplements and products decreased approximately 69.4% to approximately HK$1.9 million (2013: approximately HK$6.2 million), which is mainly due to the Group focused its product development in other segments.

Prospects

The Group will continue to drive turnover growth by placing strong emphasis on a multifaceted marketing strategy through utilising various media and channels, such as television commercials, printed media, digital media, outdoor advertising, in-store promotion, the Wisdom Club and product road shows. In addition, since June 2014, the Group has started a feasibility study, with the intention develop products such as herbal tea, herbal jelly and snacks for the Hong Kong market.

The Group has started negotiations with potential distributors in Taiwan to promote and sell the Groups products, in order to prove sales performance and reduce costs. At the same time, the Group’s products will continue be sold in the Taiwan distribution facilitator’s stores, on a non-exclusive basis, without the use of promoters.

Mr. Mark Chan, Chairman and Chief Executive Officer of the Group, said, “we have great confidence in the Group’s future prospects. The collaboration with CUCAMed Company Limited, a wholly owned subsidiary of The Chinese University of Hong Kong Foundation Limited, not only enhances the product portfolio of the Group but also increases the brand recognition of Royal Medic. We will continue to develop and promote products under the brand ‘LEGEND’. Looking forward, we will continue to drive turnover growth by placing strong emphasis on a multi-faceted marketing strategy through utilizing various media and channels.”

To see the full version of this release, including financial tables, click here:
http://photos.prnasia.com/prnk/20141112/8521406729-a

About RM Group Holdings Limited

RM Group Holdings Limited is principally engaged in the business of formulation, marketing, sales and distribution of health supplements and beauty supplements and products under its proprietary brand (including “Royal Medic”) and private label brands specifically developed for and owned by a renowned retail chain of health and beauty products in Hong Kong and Macau (the “Distribution Facilitator”). The Group outsources most of its production to its suppliers and subcontracting manufacturers and the Group distributes its products mainly through the Distribution Facilitator. According to the industry report prepared by Ipsos Hong Kong Limited, the Group ranked third as a PCM health supplements provider in Hong Kong in 2012. Its best-selling product, Royal Medic Cs-4, ranked first in terms of sales value in the Cordyceps market in Hong Kong for six consecutive years ended August 2014.

Health Care

Infinitus’ New Base in China Established for Production

admin

YINGKOU, China, Oct. 17, 2014 /PRNewswire/ — On 16 October, Infinitus Yingkou Production Base (“the Base”), the second production base of LKK Health Products Group (LKKHPG) in the Chinese mainland, was put into production, which symbolized that the strategic layout of “one South Base and one North Base” in the Chinese mainland officially formed.

Aerial View of Infinitus Yingkou Production Base

Aerial View of Infinitus Yingkou Production Base

The Base, whose ground-breaking ceremony took place in July 2012, boasts a total investment of RMB1.5 billion for the initial phase. Until now, a series of modern facilities have been constructed and put into use, including the extraction workshop, production workshops for oral liquid, capsules and tablets, the technology center and the Yingkou campus of Infinitus University. It is mainly used to produce high-quality Chinese herbal health food, but also serves as a multifunctional experience platform on corporate culture and products with well-designed visiting routes.

Its production lines have been equipped with the world’s leading technology in line with GMP, HACCP, ISO22000 and ISO9001, and characterized by low energy consumption and emission yet with high efficiency. The Product Inspection Lab has been designed to the criteria of CNAS, and the inspection project numbers and criteria reach world standards.

LKKHPG is mainly engaged in high-quality Chinese herbal health products and services, and the establishment of the Base plays an important strategic role in the development of its north China market. Mr. Harry Yeung, Senior Vice President of LKKHPG, said, “North China is a strategic spot for Chinese herbal health product enterprises due to its rich resources of raw materials and mature consumers. The Base will not only satisfy the market supply of north China, but also foster the forming of the surrounding health industry chain and the prosperity of the health industry in the northeast region.”

In south China, LKKHPG has already set up the Xinhui Production Base with accumulative investment of over RMB3 billion and the annual production capacity exceeds RMB10 billion. For the Yingkou Base, its production capacity is estimated to reach RMB18 billion in the fifth year when it is fully operated.

Mr. Yeung further added, “The two bases will form highly efficient synergy in areas like R&D, production, logistics, service and IT. This can significantly improve the production capacity to better satisfy the ever-increasing needs of Chinese herbal health products and propel the healthy development of TCM industry around the world.”

Samson Su
+86-20-3816-8859
samson.su@infinitus-int.com

Photo – http://photos.prnasia.com/prnh/20141016/0861407497

Health Care

Complementary Medicine Use Linked to Healthcare Cost Savings, Finds Frost & Sullivan

admin

– Targeted use of complementary medicines significantly reduces risk of disease-related events, hospitalisation costs and productivity losses

SYDNEY, Oct. 15, 2014 /PRNewswire/ — Escalating healthcare costs associated with the increasing burden of disease in Australia is a major challenge for government, private health insurers and individuals. Thus, there is growing pressure to find solutions to improve health outcomes and reduce healthcare expenditures. One available option is to motivate at-risk individuals to adopt a regimen that aims to reduce the risk of costly events associated with major chronic disease in terms of hospital separations and lost wage income due to illness. Use of complementary medicines among well-defined, high-risk populations can help decrease the occurrence of disease-attributed medical events and associated economic consequences.

Frost & Sullivan’s recent economic analysis, Targeted Use of Complementary Medicines: Potential Health Outcomes & Cost Savings in Australia, assesses the relationship between use of complementary medicines and potential healthcare cost savings and productivity gains. The research shows that notable net benefits can be realised through targeted use of certain scientifically substantiated complementary medicine regimens among high-risk individuals, such as calcium and vitamin D or magnesium for osteoporosis, omega-3, folic acid, B6 and B12, for cardiovascular disease (CVD), lutein and zeaxanthin for age-related eye disease, and St. John’s wort for moderate major depression.

For complimentary access to more information on this research, please contact Carrie Low Corporate Communications, at carrie.low@frost.com, with your full name, company name, job title, telephone number, company email address, company website, city, state and country.

“A less-than-healthy society leads to an increase in medical service expenditure and a loss in labour productivity. This means less tax revenue for Commonwealth, State and Territory governments and increased healthcare costs; in other words, a less-than-healthy economy,” said Frost & Sullivan Global Program Director for the Chemicals, Materials and Food Practice, Christopher Shanahan.

For example, more than $1.6 billion in healthcare cost savings and wage income gains can be realized in 2015 if all women over the age of 50 with osteoporosis or osteopenia were to use calcium and vitamin D. Additionally, by targeting all Australians over the age of 55 with diagnosed CVD, the study found that after using an omega-3 regimen, a potential net benefit yield of nearly $490 million in net cost savings and productivity gains in 2015 is realisable. Also, a St. John’s wort intervention could save $256 million in wage income gains in 2015 if all adults aged 20 and over used this regimen at preventive intake levels.

“Determining the cost-effectiveness of using certain complementary medicines requires that many factors be considered such as which disease events are preventable, the efficacy of the complementary medicine under review, and consequently, the relative cost, before an informed decision can be made,” observed Shanahan. “However, once the link between the use of certain complementary medicines with scientifically-substantiated health potential and economic benefit is better understood, the decision to use the complementary medicine will be easier to make.”

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants.

Our “Growth Partnership” supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

  • The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
  • The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact Us:     Start the discussion

Join Us:           Join our community

Subscribe:       Newsletter on “the next big thing”

Register:         Gain access to visionary innovation

Contact:
Carrie Low
Corporate Communications – Asia Pacific
P: +603-6204-5910
F: +603-6201-7402
E:  carrie.low@frost.com
http://www.frost.com

Logo – http://photos.prnasia.com/prnh/20141015/8521406003LOGO

Health Care SPT

Infinitus Advocates Daily Walk for 10,000 Steps

admin

HONG KONG, Aug. 15, 2014 /PRNewswire/ — A recent research in UK has found that 36 is the age when we suddenly realize the importance of health. Rather than waiting for a health warning call, we might as well protect our lifeline proactively.

With substantial proof of direct linkage between health and walking, Infinitus, MCMIA Foundation and Hong Kong Trade Development Council (HKTDC) jointly initiate the “Infinitus Daily Walk for 10,000 Steps” Campaign to advocate walking as a daily habit, and the kick-off ceremony took place at Hong Kong Convention and Exhibition Center on 14 August.

http://www.infinitus-int.com/news-detaile-140799763321876.html?l=en 

Vice Commissioner of State Administration of Traditional Chinese Medicine of P.R.C. Mr Yu Wenming, Secretary for MCMIA Foundation Ms. Vivien Chou, Director of Exhibitions Market Development, HKTDC, Ms. Loretta Wan, and Senior Vice President of LKK Health Products Group (LKKHPG) Mr. Harry Yeung, signed on the giant T-shirt at the ceremony to unveil the “Infinitus Daily Walk for 10,000 Steps” Campaign. Meanwhile, Infinitus also launched the “Most Beautiful 10,000-Step Walking Path Award”, and called on HK citizens to vote at http://www.facebook.com/InfinitusHongKong.

“Daily Walk for 10,000 Steps” originates from Infinitus’ unique health philosophy. “Infinitus” is the core brand of LKKHPG, and it has formulated a set of simple yet feasible practice guidance called “Missing Link of Four Regulations” as follows to foster the nurturing of healthier lifestyles among the public.

  • Diet: More vegetable less meat, eat until 70% full
  • Living: Power nap for 20 minutes and sleep before 23:00
  • Exercise: Daily walk for 10,000 steps
  • Emotion: Positive thinking

To promote “Daily Walk for 10,000 Steps”, Infinitus has already organized “Infinitus World Walking Day” in the Chinese mainland since 2010 and harvested great popularity and fruitful results. This year, the event started in June, and would walk into 12 cities all year long. Moreover, it is also coming to Hong Kong in the near future, and inviting HK citizens and foreign visitors to experience the fun and health through walking.

At the ceremony, Mr. Harry Yeung, Senior Vice President of LKKHPG and Spokesperson of Infinitus, said,” Through promoting walking at this year’s ICMCM, we aim to promote our health philosophy and the “walking day” to go global to more areas. Meanwhile, we hope more and more people from Hong Kong and abroad can become aware of benefits of walking and start to walk daily for better health.”

Samson Su
+86-20-3816-8859
samson.su@infinitus-int.com